GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
08/10/26	TWD 22.80	-0.87%	44,969
07/10/26	TWD 23.00	+1.10%	128,983
06/10/26	TWD 22.75	-0.22%	81,257
05/10/26	TWD 22.80	+1.79%	168,265
02/10/26	TWD 22.40	+1.13%	198,012

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 08/10/2026			5-day change	1st Jan Change
22.80 ^TWD	-0.87%		+2.01%	-11.46%

13/08	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
03/08	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI

Market Cap	2.57B 80.23M 71.65M 66.84M 60.72M 114M 7.77B 115M 802M 314M 3.95B 301M 295M 12.7B	P/E 2024	-11.8x	P/E 2025	-11.9x
Enterprise Value	2.35B 73.36M 65.51M 61.12M 55.52M 104M 7.11B 105M 734M 287M 3.61B 275M 269M 11.61B	EV / Sales 2024	154x	EV / Sales 2025	67.8x
Free-Float	79.89%	Yield 2024 *	-	Yield 2025	-

13/08	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
03/08	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI
11/06	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
14/05	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
15/04	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI
24/03	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate	CI
14/03	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
09/12	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program	CI
25/11	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer	CI
14/11	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
30/10/25	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis	RE
29/10/25	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis	CI
14/08/25	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

1 day	-0.87%
1 week	+2.01%
Current month	+2.01%
1 month	+2.93%
3 months	-11.63%
6 months	-1.30%
Current year	-11.46%

GlycoNex Incorporation Stock

Stocks

4168

TW0004168000

Biotechnology & Medical Research

Valuation: GlycoNex Incorporation

Chart: GlycoNex Incorporation

Latest news: GlycoNex Incorporation

Press Releases: GlycoNex Incorporation

Quotes and Performance

Price Extremes

Managers and Directors: GlycoNex Incorporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	22.25	23.55
1 month	21.05	23.55
Current year	21.05	30
1 year	20.55	30
3 years	15.6	31.85
5 years	15.6	46.9
10 years	10.2	46.9

Manager	Title	Age	Since
Mei Chun Yang CEO	Chief Executive Officer	-	01/01/2019
Dih Fen Wu DFI	Director of Finance/CFO	-	01/01/2010
Yao Hua Lue IRC	Investor Relations Contact	-	12/11/2012

Director	Title	Age	Since
Tong Hsuan Chang CHM	Chairman	-	01/02/2001
Kao Chung Tsai BRD	Director/Board Member	64	-
Ling-Chun Tsai BRD	Director/Board Member	-	25/05/2012

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLYCONEX INCORPORATION	-0.87%	+2.01%	-6.94%	-19.86%	81.21M
WUXI APPTEC CO., LTD.	-3.19%	-3.19%	+44.60%	+87.98%	74.68B
ARGENX SE	-15.86%	-16.16%	+2.68%	+51.09%	58.7B
LONZA GROUP AG	-2.39%	+0.50%	+3.41%	+31.33%	48.36B
REVOLUTION MEDICINES, INC.	-8.22%	-10.00%	+287.52%	+627.56%	43.05B
IQVIA HOLDINGS INC.	-0.63%	-1.63%	+27.85%	+28.53%	42.48B
BEONE MEDICINES AG	-4.35%	-3.10%	-0.98%	+101.20%	41.39B
CELLTRION, INC.	-2.13%	+1.07%	+7.51%	+50.31%	31.29B
BIONTECH SE	-2.98%	-4.44%	-12.92%	-15.33%	23.93B
INSMED INCORPORATED	-1.89%	-8.63%	-38.68%	+304.79%	22.22B
Average	-4.22%	-2.19%	+31.41%	+124.76%	38.62B
Weighted average by Cap.	-5.22%	-1.88%	+42.05%	+133.31%

	2024	2025
Net sales	14.7M 460K 411K 383K 348K 655K 44.53M 661K 4.6M 1.8M 22.63M 1.73M 1.69M 72.77M	37.86M 1.18M 1.06M 986K 896K 1.69M 115M 1.7M 11.84M 4.63M 58.27M 4.45M 4.35M 187M
Net income	-230M -7.18M -6.42M -5.98M -5.44M -10.23M -696M -10.33M -71.85M -28.1M -354M -26.97M -26.39M -1.14B	-235M -7.36M -6.57M -6.13M -5.57M -10.48M -712M -10.58M -73.58M -28.78M -362M -27.62M -27.02M -1.16B
Net Debt	-442M -13.83M -12.35M -11.52M -10.46M -19.69M -1.34B -19.88M -138M -54.09M -680M -51.91M -50.79M -2.19B	-220M -6.87M -6.14M -5.72M -5.2M -9.78M -665M -9.88M -68.72M -26.88M -338M -25.8M -25.24M -1.09B